Clinical trials: CD160
Corneal Graft Rejection, CD160
CD160 Expression in Corneal Vessels
Despite improvements in corneal transplantation, anti-angiogenic and anti-lymphangiogenic factors remain to be be identified. CD160 is an anti-angiogenic target: its expression seems to be restricted to some immune cells and to…
- Conditions
- Corneal Graft Rejection, CD160, Angiogenesis, Lymphangiogenesis
- Trial name
- NCT05009407
- Testing
- Immunohistochemistry and clinical analyses on patients and corneas
- Where
- France
- Volunteers
- 43 people
- Sponsor
- CHU de Reims
Biliary Tract Neoplasms, Cholangiocarcinoma, Intrahepatic
Safety and Efficacy of CD160-Enhanced Autologous Antigen-Specific T-Cells (BTC-Ag-T) in Advanced Biliary Tract Cancer
BTC-Ag-T (ACH-AgT001) is an autologous experimental T-cell therapy designed for advanced biliary tract cancer. This is an open-label, single-arm Phase 1 study to evaluate the safety, tolerability, and preliminary efficacy of…
- Conditions
- Biliary Tract Neoplasms, Cholangiocarcinoma, Intrahepatic, Cholangiocarcinoma, Extrahepatic, Cholangiocarcinoma, Perihilar
- Trial name
- NCT07614061
- Testing
- BTC-Ag-T (ACH-AgT001), Cyclophosphamide and Fludarabine
- Where
- China
- Volunteers
- 18 people
- Sponsor
- Shanghai Zhongshan Hospital
Melanoma
Study of CD160, an Activating NK Cell Receptor, in Melanoma: a Potential Therapeutic Target?
Although immunotherapy revolutionized melanoma outcomes over the last 10 years, only 40-50% of patients respond to treatments and 25% develop acquired resistances.
- Trial name
- NKCD160MEL (NCT04477876)
- Volunteers
- 55 people, healthy volunteers welcome
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Surgical Retinal
CD160 Expression in Retinal Vessels is Associated With Retinal Neovascular Diseases
The aims of this study were to analyze CD160 expression in both normal and pathological eyes from human adults to evaluate association between CD160 presence on endothelial cells from blood vessels and retinal vascular disease
- Trial name
- NEOVASC-CD160 (NCT03940664)
- Testing
- immunohistochemistry on Formalin fixed and paraffin embedded blocks
- Where
- France
- Volunteers
- 75 people
- Sponsor
- CHU de Reims